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INTRODUCTION
Although secondary involvement of the adrenal gland has
been reported to occur in up to 25% of patients with non-
Hodgkin’s lymphoma (NHL) (1), primary adrenal lymphoma
(PAL) is very rare, with only about 80 cases reported in the
English language literature (2). Treatment of PAL is similar
to that of other types of lymphoma, but prognosis is poor.
Therapeutic modalities include surgery, combination chemo-
therapy, and/or radiotherapy. Among the chemotherapy reg-
imens utilized are CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone), CVP (cyclophosphamide, vin-
cristine, and prednisone), and MACOP-B (adding methotrex-
ate and bleomycin) (2). Here, we describe a patient with pri-
mary bilateral adrenal diffuse large B-cell lymphoma who
achieved complete remission after treatment with rituximab
plus CHOP (R-CHOP). 
CASE REPORT
A 52-yr-old man with no prior medical history was admit-
ted for a 3-month history of fever and progressive fatigue. He
appeared chronically ill, but alert. Blood pressure was 100/70
mmHg, pulse rate was 102 bpm, respiratory rate was 22 bpm,
and body temperature was 38.5℃. Examination of head and
neck was unremarkable; no abnormality was found in chest;
no hepatosplenomegaly or mass was detected in the abdomen;
and there was no evidence of lymphadenopathy or abnormal
skin lesions. 
A complete blood count showed hemoglobin 10.4 g/dL,
hematocrit 30.0%, white blood cell count 5,000/μ L, and
platelet count 104,000/μ L. Sodium level was 126 mM/L
(normal range, 133-150 mM/L), but potassium and calcium
levels were normal. Serum β 2-microglobulin concentration
was 4.7 μ g/mL (normal range, 1-2.4 μ g/mL), serum lactate
dehydrogenase (LDH) level was 476 IU/L (normal range, 120-
250 IU/L), serum cortisol concentration at 8 AM was 2.9 μ g/
dL (normal range, 7-25 μ g/dL), plasma ACTH level at 8 AM
was 210 pg/mL (normal range, 9-52 pg/mL), and serum aldos-
terone concentration was 56.2 pg/mL (normal range, 20-160
pg/mL). Urinalysis showed that 24 hr excretion of vanillyl-
mandelic acid was 5.9 mg/day (normal range, 0-8 mg/day),
of epinephrine was 21.5 μ g/day (normal range, 0-20 μ g/day),
of norepinephrine was 202.1 μ g/day (normal range, 1-130 μ g/
day), and of total metanephrine was 0.6 mg/day (normal range
0-1.3 mg/day). Rapid cosyntropin (analog of ACTH) stim-
ulation test, using 250 μ g of intravenous cosyntropin, demon-
strated plasma cortisol concentrations at 0, 30 and 60 min
of 9.5, 10.0 and 10.5 μ g/dL, respectively (reference range, at
least 7 μ g/dL at 0 min, 16 μ g/dL at 30 min, and 18 μ g/dL at
60 min), strongly suggesting adrenal insufficiency. 
Chest radiography was normal without evidence of hilar
lymphadenopathy. Computed tomography (CT) scans of ab-
domen and pelvis demonstrated large bilateral adrenal masses.
The right adrenal gland measured 5.8×2.7 cm, and the left
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A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving
Complete Remission with Rituximab-CHOP Chemotherapy
Primary adrenal lymphoma is a very rare extranodal lymphoma; its clinical features
consist of a high incidence of bilateral adrenal involvement and diffuse large B-cell
lymphoma. We report a patient with primary bilateral adrenal diffuse large B-cell
lyphoma who achieved complete remission with R-CHOP (rituximab-cyclophos-
phamide, doxorubicin, vincristine, and prednisone) chemotherapy. A 52-yr-old man
presented with fever and progressive fatigue for 3 months. Computed tomography
(CT) scans of the abdomen and pelvis demonstrated large bilateral adrenal mass-
es, and a needle biopsy of the left adrenal mass revealed diffuse large B-cell lym-
phoma. After 6 cycles of R-CHOP chemotherapy, CT scans showed no residual
disease. To our knowledge, this is the second report to date of a patient with primary
bilateral adrenal diffuse large B-cell lymphoma who achieved complete remission
using R-CHOP chemotherapy.
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sion (Fig. 1). 
A CT-guided core needle biopsy of the left adrenal mass
was performed. The tumor was comprised of large cells, which
were immunohistochemically positive for CD20, but nega-
tive for CD3 and CD30. The Ki-67 labeling index was about
90%. The tumor was diagnosed as a diffuse large B-cell lym-
phoma (Fig. 2).
Bone marrow biopsy was negative for lymphomatous invol-
vement. An F-18 fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) scan showed intense FDG accumu-
lation in both adrenal glands. There was no abnormal FDG
uptake in the rest of the body (Fig. 3).
The patient was administered adrenal hormone replacement
therapy with 20 mg hydrocortisone at 8 AM and 10 mg at
4 PM. He was also administered R-CHOP chemotherapy,
consisting of rituximab (375 mg/m
2 i.v.), cyclophosphamide
(750 mg/m
2 i.v.), doxorubicin (50 mg/m
2 i.v.), and vincristine
(1.4 mg/m
2 i.v.), on day 1, and prednisolone (100 mg p.o.)
on days 1-5, every 3 weeks. After completing 6 cycles of R-
CHOP chemotherapy, there was no evidence of tumor on fol-
low-up CT and FDG-PET scans (Fig. 4). To date, this patient
has been followed regularly at our outpatient clinic for the
past 12 months, with no evidence of tumor recurrence.
DISCUSSION
PAL is a very rare lymphoma, with only about 80 cases re-
ported in the English language literature (2, 3). Histologically,
the most common type is diffuse large B-cell lymphoma, with
most originating in both adrenal glands (Table 1). PAL is most
common in elderly men; the mean age at diagnosis is 68 yr
and the male-to-female ratio is 2.2:1. Clinical symptoms of
PAL include fever, weight loss, local pain, and symptoms of
adrenal insufficiency (8). Immune dysfunction may be a predis-
posing factor in some patients (3). A review of 55 PAL patients
showed that 8 (15%) had a concurrent or past history of carci-
noma, 2 (4%) had human immunodeficiency virus (HIV) infec-
tion, and 7 (13%) had concomitant autoimmune disease (8).
On CT and magnetic resonance imaging (MRI), PALs tend
to appear as complex masses of variable density and often have
areas of necrosis and/or hemorrhage, with most tumors being
bilateral (8). Because most PAL patients have adrenal involve-
ment only, without any nodal involvement, whole body FDG-
PET, which measures increased glucose metabolism and has
been used in tumor diagnosis and staging, in monitoring res-
ponse to treatment, and detecting recurrence, has shown in-
tense FDG uptake only in the adrenal glands (2). In our
patient, whole-body FDG-PET demonstrated FDG uptake
in the adrenal masses, with no evidence of abnormal uptake
in extraadrenal regions.
Tissue samples can be obtained by CT- or ultrasound-guid-
ed biopsy or by surgical excisional biopsy (3, 8, 11). Histo-
logically, the most common type of PAL is diffuse large B-
cell lymphoma (2, 3, 8). These neoplastic cells express anti-
gens specific to B lymphocytes, such as CD20, CD74, CDw75,
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Fig. 2. CT-guided core needle biopsy of the left adrenal mass show-
ing a tumor comprised of large cells, immunohistochemically pos-
itive for CD20 but negative for CD3 and CD30. The Ki-67 labeling
index was about 90%. The tumor was diagnosed as a diffuse large
B-cell lymphoma. 
Fig. 1. Abdominal pelvic CT scan showing bilateral adrenal masses. 
Fig. 3. F-18 fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) scan showing intense FDG accumulation in both ad-
renal glands. There was no abnormal FDG uptake in the rest of
the body.and CD79a, while not expressing antigens specific to T lym-
phocytes, such as CD3, CD5, CD43, and CD45RO (26).
Because of the rarity of PAL, therapeutic regimens have
not been defined in detail (2), with most patients treated with
regimens similar to those used to treat other types of lym-
phoma. Therapeutic modalities include surgery, combination
chemotherapy, and radiation (8). Most patients with PAL
have been treated with CHOP and the remainder with CVP
or MACOP-B (2). The roles of radiation therapy and surgical
excision of the adrenal glands in the context of bilateral invol-
vement are not known (3). The prognosis of patients with PAL
is very poor, with uncertain duration of survival (3, 8, 22).
Poor prognosis is thought to be due to advanced age at diag-
nosis, large tumor size, increased LDH level, bilateral adrenal
involvement (regarded as stage IV disease), and adrenal insuf-
ficiency at the time of presentation, indicating extensive adre-
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Fig. 4. Follow-up CT and FDG-PET scans after 6 cycles of R-CHOP chemotherapy showing no evidence of tumor.
A, adriamycin; B, bleomycin; B/L, bilateral; C, cyclophosphamide; CR, complete remission; D, dexamethasone; E, epirubicin; Et, etoposide; FUO, fever
of unknown origin; H, doxorubicin; IT, intrathecal; L, left; M, mitozantrone; Met, metastasis; MTX, methotrexate; mo, month; NM, not mentioned; NS, not
specified; O, vincristine; P, prednisolone; R, right; Wt, weight. 
Age/sex Reference Year Initial  symptoms Treatment Outcome
72/F Utsunomiyal et al. (4) 1992 Fatigue, fever Surgery, CHP Died 1yr later
69/M Kato et al. (5) 1996 Abdominal pain, Wt. loss NS NS
61/F Al-Fiar et al. (6) 1997 Wt. loss, nausea CHOP Died 11 mo later
55/M Nasu et al. (7) 1998 Fever, Wt. loss, hyperpigmentation BACOD-Et + CHOP Died 8 mo later
64/F Hsu et al. (9) 1999 FUO, nausea, vomiting COP Died 15 day later
27/M Salvatore, Ross (10) 1999 Nausea, vomiting, fever CHOP NS
63/M Yamamoto et al. (12) 1999 Idiopathic thrombocytopenic purpura ACOEP CR 6 yr
69/F Kuyama et al. (13) 2000 Fatigue, Wt. loss CHOP CR 50 mo
62/M Clemens, Pins (14) 2000 Fever, fatigue, Wt. loss CHOP + IT MTX NS
73/F Suga et al. (15) 2000 NM Chemotherapy No response
62/F Yamashita et al. (16) 2000 NM Chemotherapy Response on CT
56/F Viswanathan, Middleton (17) 2001 FUO NM NM
71/M Schocket et al. (18) 2002 Decreased visual acuity CHOP CR 7 yr
61/M Hahn et al. (19) 2002 Abdominal pain CEOP, radiation improved
80/M Lu et al. (20) 2002 Nausea, Wt. loss, hyperpigmentation COP Died after 4 mo
NM Xu et al. (21) 2003 Wt. loss, fever Surgery Died in 3 mo
NM Xu et al. (21) 2003 Wt. loss, fever CHOP Died after 2 cycles
59/F Wang et al. (22) 2003 NM CHOP Died after 6 mo
86/M Gillett, Haak (23) 2003 Lethargy, sweats, Wt. loss CEOP CR 10 mo
55/M Grigg, Connors (3) 2003 Hypoadrenalism Chemotherapy Died 
70/M Zar et al. (24) 2004 Wt. loss, abdominal pain CHOP Died after 1 cycle
60/F Singh et al. (25) 2004 Headache CHOP, radiation Died after 9 mo
27/M Singh et al. (25) 2004 Right leg swelling CHOP, radiation CR 8 mo
55/F Singh et al. (25) 2004 Abdominal discomfort CHOP Died after 7 mo
67/M Kumar et al. (2) 2005 Fatigue, Wt. loss, fever Chemotherapy CR
54/F Airaghi et al. (27) 2006 Paresthesia in left cheek Chemotherapy CR
Table 1. List of documented cases of primary bilateral adrenal diffuse large B-cell lymphoma in the English language literaturenal destruction (3). 
The most common regimen of PAL is CHOP, with a 71-yr-
old man with primary bilateral adrenal diffuse large B-cell
lymphoma reported to have continued in complete remission
for 7 yr after treatment with the CHOP regimen (18). Recent
evidence suggests that the outcome of elderly patients with
diffuse large B-cell lymphoma is improved by the addition
of rituximab to CHOP (28). Our patient, who was adminis-
tered 6 cycles of R-CHOP every 3 weeks, showed complete
remission on follow-up CT and FDG-PET. Although a 62-
yr-old man with primary bilateral diffuse large B-cell lym-
phoma who was treated with a left adrenalectomy, R-CHOP,
radiotherapy, and high-dose chemotherapy with autologous
peripheral blood stem cell transplantation, has been disease-
free for 2 yr, this report was in Japanese (29). Moreover, in
contrast to this patient, our patient received only R-CHOP
chemotherapy, without surgery, radiation or high-dose therapy.
In conclusion, this may be the second report of a patient with
primary bilateral adrenal diffuse large B-cell lymphoma who
achieved complete remission using R-CHOP chemotherapy.
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